Research progress on PFKFB3 gene in fundus neovascular diseases
10.3760/cma.j.cn511434-20250116-00026
- VernacularTitle:PFKFB3基因在眼底新生血管性疾病中的研究进展
- Author:
Ping LIU
1
;
Kaixuan CUI
;
Yaling LIU
;
Xinyu ZHAO
;
Zhenquan WU
;
Zhen YU
;
Peiling WEI
;
Guoming ZHANG
Author Information
1. 山东第二医科大学临床医学院, 潍坊 261000
- Publication Type:Journal Article
- Keywords:
PFKFB3 gene;
Fundus neovascular diseases;
Glycolysis;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2025;41(10):812-818
- CountryChina
- Language:Chinese
-
Abstract:
Fundus neovascularization is a significant cause of ocular diseases, mainly including retinal neovascularization and choroidal neovascularization. Anti-vascular endothelial growth factor therapy, though effective, has limitations such as a short half-life, non-responsiveness, and drug resistance. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a key regulator of glycolysis, affects the generation of pathological blood vessels by modulating the metabolism of vascular endothelial cells. Small molecule inhibitors targeting PFKFB3 protein have been confirmed in animal and cell models to significantly inhibit pathological angiogenesis, showing good therapeutic potential. However, most of them are still in the preclinical research stage. In the future, it is necessary to further investigate the mechanism of PFKFB3 gene, optimize the specificity and safety of the inhibitors, and explore the effects of combining them with existing therapies, so as to provide new strategies for the treatment of fundus neovascular diseases.
